Clinical Trial Update: Lucentis to Treat Retinopathy of Prematurity (ROP) 3 Plus Disease [NA]

View source ↗

Summary

A completed clinical trial evaluating Lucentis (ranibizumab) for treating retinopathy of prematurity is reported. The study focuses on ROP with 3 Plus disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinopathy of Prematurity

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Kantonsspital Aarau | Conditions: Retinopathy of Prematurity | NA | Status: COMPLETED